Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study – data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA)

Figures & data

Table 1 Patients’ clinical complexity

Comorbidities	n (%)
Hypertension	156 (68.7)
CHF	99 (43.6)
Diabetes	57 (25.1)
CAD	65 (28.7)
Previous MI	47 (20.7)
PAD	63 (27.7)
Previous stroke or TIA	42 (18.5)
CIRSc >3	180 (79.3)

Note: Values are expressed as n, total number, and (%), percentage.

Abbreviations: CAD, coronary artery disease; CHF, chronic heart failure; CIRSc, Cumulative Illness Rating Scale complexity; MI, myocardial infarction; PAD, peripheral artery disease; TIA, transient ischemic attack.

Table 2 Patients’ clinical details according to the prescribed NOAC therapy

	Apixaban 2.5 mg BID (n=86)	Apixaban 5 mg BID (n=35)	Dabigatran 110 mg BID (n=31)	Dabigatran 150 mg BID (n=14)	Rivaroxaban 15 mg QD (n=18)	Rivaroxaban 20 mg QD (n=40)
Age, years	84.13±5.54	75.42±7.31	81.77±5.97	72.86±5.88	81.83±7.82	76.62±10.39
Weight, kg	69.28±15.39	76.11±13.7	67.65±12.15	76.97±17.97	64.86±9.56	73.99±13.98
eGFR, mL/min	46.62±15.75	72.11±24.67	54.55±20.55	87.58±28.82	54.02±21.73	73.48±22.72

Note: Values are expressed as n, total number, and mean ± SD.

Abbreviations: BID, bis in die; eGFR, estimated glomerular filtration rate; NOAC, non-vitamin K oral anticoagulant; QD, quaque die.

Figure 1 Event-free survival: bleeding-free survival plot (A); hospitalization-free survival plot (B).

Table 3 Occurrence of MB and CRNMB according to the prescribed NOAC therapy

NOAC	MB (n=10)	CRNMB (n=13)
Apixaban 2.5 mg BID	3 (3.49)	4 (4.65)
Apixaban 5 mg BID	2 (5.71)	3 (8.57)
Dabigatran 110 mg BID	1 (3.23)	2 (6.45)
Dabigatran 150 mg BID	3 (21.43)	1(7.14)
Rivaroxaban 15 mg QD	0 (0)	3 (16.67)
Rivaroxaban 20 mg QD	1 (2.5)	0 (0)

Notes: Values are expressed as n, total number, and (%), percentage.

Abbreviations: BID, bis in die; CRNMB, clinically relevant non-major bleeding; MB, major bleeding; NOAC, non-vitamin K oral anticoagulant; QD, quaque die.

Table 4 Clinical details of patients on a reduced dose of NOAC compared to those on full dose

	Apixaban 2.5 mg BID	Full dose	P-value
Age, years	84.13±5.54	77.74±8.52	<0.001
Weight, kg	69.28±15.39	72±13.91	0.13
eGFR, mL/min	46.62±15.75	67.05±25.25	<0.001
CIRSc	5.21±1.73	4.83±1.75	0.202
CIRSs	2±0.31	1.91±0.29	0.109
HGB, g/dL	11.8±1.68	12.59±1.72	<0.001
	Dabigatran 110 mg BID	Full dose	P-value
Age, years	81.77±5.97	80±8.41	0.263
Weight, kg	67.65±12.15	71.62±14.84	0.263
eGFR, mL/min	54.55±20.55	60.06±24.64	0.348
CIRSc	5.5±2.04	4.93±1.7	0.158
CIRSs	2.01±0.31	1.94±0.3	0.234
HGB, g/dL	11.73±0.45	11.68±1.5	0.672
	Rivaroxaban 15 mg QD	Full dose	P-value
Age, years	81.83±7.82	80.11±8.16	0.367
Weight, kg	64.86±9.56	71.65±14.8	0.062
eGFR, mL/min	54.02±21.73	59.75±24.33	0.433
CIRSc	5.29±1.68	4.97±1.75	0.463
CIRSs	1.96±0.32	1.95±0.3	0.757
HGB, g/dL	12.32±1.6	12.24±1.77	0.7

Notes: Values are expressed as mean ± SD. P<0.05 was considered as significant.

Abbreviations: BID, bis in die; c, complexity; CIRS, Cumulative Illness Rating Scale; eGFR, estimated glomerular filtration rate; HGB, hemoglobin; NOAC, non-vitamin K oral anticoagulant; QD, quaque die; s, severity.